Among the observed mechanisms demonstrated to abrogate sensitivity to anti-angiogenic therapy is the observation that VEGF inhibitor therapy induces hypoxia dependent alterations in gene expression resulting in an increase in the invasive and/or metastatic capabilities of different tumor types [7, 10–12]. This evidence concerns the gene VEGFA and neoplasm.